Recent Posts
Connect with:
Thursday / May 30.
HomeminewsOptometrist Warehouse Diabetic Retinopathy AI Study

Optometrist Warehouse Diabetic Retinopathy AI Study

Optometrist Warehouse has commenced its clinical journey with a Memorandum of Understanding (MoU) to collaborate with Singaporean artificial intelligence (AI) company EyRIS, on a ground-breaking study focussed on the effectiveness of AI in screening diabetic retinopathy.

The study aims to showcase the potential benefits of AI-driven solutions in improving patient outcomes and cost-effectiveness.

Diabetic retinopathy, a common complication of diabetes, is a leading cause of blindness among adults globally. According to the Australian Diabetes Society, over 1.5 million Australians are currently living with diabetes, and this number is projected to increase significantly over the next decade. Early detection and intervention are crucial to prevent vision loss and related complications.

The study will leverage EyRIS’s advanced AI algorithms and Optometrist Warehouse expertise with links to the extensive network of pharmacies across Australia of Chemist Warehouse to evaluate the effectiveness of AI-driven screening for diabetic retinopathy.

By using EyRIS’s cutting-edge technology, which analyses retinal images for signs of diabetic retinopathy, the study aims to demonstrate the efficacy and efficiency of AI in identifying patients at risk and facilitating early intervention.

We are proud to collaborate with EyRIS to explore the possibilities of AI in diabetic retinopathy screening

Mr Lai Teik Kin, CEO of EyRIS, expressed his enthusiasm about the collaboration, stating, “We are thrilled to partner with Optometrist Warehouse on this ground-breaking study. By harnessing the power of AI, we can revolutionise diabetic retinopathy screening, ensuring early detection and timely treatment for patients.

“Our technology has the potential to transform healthcare delivery, saving lives and reducing healthcare costs.”

Optometrist Warehouse, which has a stated mission to transform health outcomes by systematically connecting pharmacy with optometry, recognises the transformative impact of AI in the field of medicine.

Peter Larsen, MD of Optometrist Warehouse, and a recognised leader in eye health service improvement, said, “We are proud to collaborate with EyRIS to explore the possibilities of AI in diabetic retinopathy screening.

“This study aligns with our mission to improve healthcare outcomes for all Australians. By leveraging EyRIS’s AI expertise, we can enhance the accessibility and affordability of early screening, thereby empowering patients and healthcare providers alike.”

The collaboration between EyRIS and Optometrist Warehouse underscores the commitment of both organisations to leverage technological advancements for the betterment of healthcare. The potential benefits of AI-driven diabetic retinopathy screening include reducing the burden on healthcare systems, minimising unnecessary referrals, and enabling targeted interventions, ultimately improving patient outcomes.

The study run for 36 months and involve a large sample size of diabetic patients across various regions in Australia.